Processa Pharmaceuticals, Inc. — Director's Dealing 2023

Jan 4, 2023

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Processa Pharmaceuticals, Inc. (PCSA)
CIK: 0001533743
Period of Report: 2022-12-31

Reporting Person: Pannu Geraldine (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2022-12-31	Common Stock	M	18208	—	Acquired	29477	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2023-01-01	Restricted Stock	$0	A	30000	Acquired		Common Stock (30000)	Direct

Footnotes

F1: Vesting of time-based restricted shares.

F2: The restricted stock vests on the earliest of one year from date of grant or the next annual meeting of stockholders.